Cargando…

Expression of insulin‐like growth factor‐1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes

In patients with breast cancer, markers of aggressiveness such as dysregulation of the insulin‐like growth factor receptor (IGF1R) system and E‐cadherin loss are commonly observed. Reduced IGF1R expression is correlated with decreased E‐cadherin levels and increased cell motility. We assessed IGF1R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spiliotaki, Maria, Mavroudis, Dimitris, Kokotsaki, Maria, Vetsika, Eleni‐Kyriaki, Stoupis, Ioannis, Matikas, Alexios, Kallergi, Galatea, Georgoulias, Vassilis, Agelaki, Sofia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748482/ https://www.ncbi.nlm.nih.gov/pubmed/28766847 http://dx.doi.org/10.1002/1878-0261.12114

Ejemplares similares

Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2015)

Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy
por: Spiliotaki, Maria, et al.
Publicado: (2014)

Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2011)

Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2008)

Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer
por: Papadaki, Maria A, et al.
Publicado: (2014)

Hypoxia-inducible factor-1α and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2009)

Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer
por: Polioudaki, Hara, et al.
Publicado: (2015)

Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse
por: Saloustros, Emmanouil, et al.
Publicado: (2011)

Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients
por: Agelaki, Sofia, et al.
Publicado: (2016)

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer
por: Agelaki, Sofia, et al.
Publicado: (2015)

CD8(+) PD-1(+) T-cells and PD-L1(+) circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance?
por: Kotsakis, Athanasios, et al.
Publicado: (2019)

Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer
por: Kallergi, Galatea, et al.
Publicado: (2018)

Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer()
por: Matikas, Alexios, et al.
Publicado: (2017)

A Circulating Subpopulation of Monocytic Myeloid-Derived Suppressor Cells as an Independent Prognostic/Predictive Factor in Untreated Non-Small Lung Cancer Patients
por: Vetsika, Eleni-Kyriaki, et al.
Publicado: (2014)

Role of circulating free DNA in colorectal cancer
por: Matikas, Alexios, et al.
Publicado: (2016)

Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients
por: Ntzifa, Aliki, et al.
Publicado: (2021)

Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer
por: Messaritakis, Ippokratis, et al.
Publicado: (2017)

Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
por: Papadaki, Maria A., et al.
Publicado: (2021)

Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients
por: Kotsakis, Athanasios, et al.
Publicado: (2016)

PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC)
por: Pantazaka, Evangelia, et al.
Publicado: (2022)

Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer
por: Papadaki, Chara, et al.
Publicado: (2018)

Correction to: Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer
por: Papadaki, Chara, et al.
Publicado: (2022)

Immune Checkpoint and EMT-Related Molecules in Circulating Tumor Cells (CTCs) from Triple Negative Breast Cancer Patients and Their Clinical Impact
por: Vardas, Vasileios, et al.
Publicado: (2023)

Small Extracellular Vesicles in Pre-Therapy Plasma Predict Clinical Outcome in Non-Small-Cell Lung Cancer Patients
por: Vetsika, Eleni-Kyriaki, et al.
Publicado: (2021)

Distinct features of circulating microparticles and their relationship with disease activity in inflammatory bowel disease
por: Voudoukis, Evangelos, et al.
Publicado: (2016)

The Place of Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer
por: Matikas, Alexios, et al.
Publicado: (2015)

Functional Analysis of Viable Circulating Tumor Cells from Triple-Negative Breast Cancer Patients Using TetherChip Technology
por: Vardas, Vasileios, et al.
Publicado: (2023)

Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI
por: Nikolaou, Christos, et al.
Publicado: (2015)

Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer
por: Papadaki, Chara, et al.
Publicado: (2019)

PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study
por: Tzanikou, Eleni, et al.
Publicado: (2019)

PARP-1 Expression and BRCA1 Mutations in Breast Cancer Patients’ CTCs
por: Sklias, Thodoris, et al.
Publicado: (2022)

Detyrosinated α-Tubulin, Vimentin and PD-L1 in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer (NSCLC) Patients
por: Katsarou, Spyridoula D., et al.
Publicado: (2022)

Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer
por: Stergiopoulou, Dimitra, et al.
Publicado: (2023)

Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer
por: Matikas, Alexios, et al.
Publicado: (2022)

KRAS Genotypic Changes of Circulating Tumor Cells during Treatment of Patients with Metastatic Colorectal Cancer
por: Kalikaki, Aristea, et al.
Publicado: (2014)

Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study
por: Emmanouilides, Christos, et al.
Publicado: (2007)

Favorable Clinical Course of Patients Experiencing Bevacizumab-Induced Proteinuria
por: Saloustros, Emmanouil, et al.
Publicado: (2010)

Prognostic Role of Circulating Tumor Cells in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel: A Prospective Biomarker Study
por: Koinis, Filippos, et al.
Publicado: (2023)

What's new on circulating tumor cells? A meeting report
por: Lianidou, Evi S, et al.
Publicado: (2010)

Clinical Relevance of Mesenchymal- and Stem-Associated Phenotypes in Circulating Tumor Cells Isolated from Lung Cancer Patients
por: Pantazaka, Evangelia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nqk251vkpdp22e7lbg3hr8j6k0